UPDATE: Oppenheimer Starts Cyclacel Pharmaceuticals (CYCC) at Outperform, $17 PT
Tweet Send to a Friend
(Updated - April 30, 2021 5:54 AM EDT)
Oppenheimer analyst Kevin DeGeeter initiates coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Kevin DeGeeter initiates coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
